Close Search X

Oncotype DX Genomic Prostate Score

Interpreting GPS Results

Predict both clinical risk and tumor aggressiveness

Oncotype DX GPS is proven to be an independent predictor of:both clinical risk and tumor aggressiveness after radical prostatectomy for patients with biopsy Gleason scores of 3+3 and 3+41-3.

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report.


See sample reports

For patients with:

Getting your results

Most Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Genomic Health Laboratory. You can access the results through the online physician portal or receive the report by fax.

Start Report Guide
Start Report Guide
Page 1 2
Download PDF
Start Report Guide
Start Report Guide
Start Report Guide
Page 1 2 3

MORE TOPICS:

  • Explaining test results to patients
  • Publications
  • Case Studies
    • REFERENCES

    1. Van Den Eeden et al. AUA 2017. Abstract 17-6551.
    2. Klein et al. Eur Urol. 2014.
    3. Cullen et al. Eur Urol. 2014.

    *Adverse pathology defined as Gleason ≥4+3 and/or pT3+.
    National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

    One Urologist's Perspective

     

    Ketan Badani, MD teaches and practices urology at Mount Sinai. Hear how the Oncotype DX GPS test helps him feel much more confident in treatment option discussions with patients.

    Patient Video:
    What to Expect

     

    Use this video to help your patients understand why you've ordered them the Oncotype DX GPS test.

    Patient Video:
    Understanding Your Results

     

    This video helps your patients prepare before coming in to discuss their results with you.

    Stay in Touch

    Have a specific question? Want to keep up with our latest news? We're here for you.

     Contact Us
    Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
    In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Breast Recurrence Score, Colon Recurrence Score, Genomic Prostate Score, AR-V7 Nucleus Detect, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter," DCIS Score, and GPS are pending registered trademarks, of Genomic Health, Inc. All other trademarks are the properties of their respective owners.
    Making cancer care smarter.™